GHRP-2

Overview

GHRP-2 (Growth Hormone Releasing Peptide-2), also known as Pralmorelin, is a second-generation synthetic hexapeptide that stimulates growth hormone release through the ghrelin receptor. Developed as an improvement over first-generation GHRP-6, it offers potent GH stimulation with somewhat reduced appetite effects.

GHRP-2 occupies a middle ground in the GHRP family - more potent than Ipamorelin but with fewer side effects than GHRP-6, making it a popular choice for those seeking significant GH elevation.

Key Characteristics

• Origin: Synthetic hexapeptide (6 amino acids)
• Classification: Second-generation GHRP, Ghrelin receptor agonist
• Sequence: D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2
• Distinguishing Feature: Balanced potency/side effect profile
• Approved Use: Diagnostic agent in Japan (Pralmorelin)

The GHRP Spectrum

GHRP-2 offers potency similar to GHRP-6 with reduced (but not eliminated) appetite stimulation.

Mechanism

Primary Mechanisms

1. Ghrelin Receptor (GHS-R1a) Activation

GHRP-2 is a potent ghrelin mimetic:

• Binds to growth hormone secretagogue receptor in pituitary
• Triggers calcium signaling cascades
• Stimulates GH release from somatotrophs
• More selective than GHRP-6 for GH release

2. Hypothalamic Effects

GHRP-2 also acts on the hypothalamus:

• Stimulates GHRH release
• Suppresses somatostatin release
• Creates amplified pituitary response
• Dual action enhances overall effect

3. Moderate Appetite Stimulation

Unlike GHRP-6's intense hunger:

• Appetite increase present but manageable
• Most prominent 20-30 minutes post-injection
• Duration shorter than GHRP-6
• Can be timed strategically around meals

4. Secondary Hormone Effects

GHRP-2 affects other hormones:

• Modest cortisol elevation (dose-dependent)
• Modest prolactin elevation (dose-dependent)
• Effects less pronounced than Hexarelin
• Generally not clinically significant at standard doses

Research

Growth Hormone Release

Clinical Studies

GHRP-2 has been studied extensively:

• Reliable, dose-dependent GH release
• Peak GH levels 30-60 minutes post-injection
• Greater magnitude than Ipamorelin
• Consistent response over time

Comparative Potency

Research shows:

• Similar GH release to GHRP-6
• 2-3x greater GH release than Ipamorelin
• Synergistic with GHRH analogs
• Response varies by age and body composition

Clinical Applications

GH Deficiency Diagnosis

Approved in Japan for:

• Provocative testing of GH secretion
• Diagnosis of growth hormone deficiency
• Assessment of pituitary function

Body Composition

Studies indicate:

• Increased lean body mass
• Decreased fat mass
• Improved muscle strength
• Enhanced recovery from exercise

Anti-Aging Research

Somatopause Research

Studies in older adults show:

• Effective GH stimulation despite age
• Improved sleep quality
• Enhanced physical performance
• Potential cognitive benefits

Cardiovascular Effects

Cardioprotective Research

Some studies suggest:

• Potential cardioprotective effects
• Reduced ischemic damage in animal models
• May improve cardiac function
• Needs more human research

Dosing

Research Protocols

Optimal Timing

Best Times for Injection

• Upon waking (fasted state)
• Post-workout
• Before bed (important for sleep GH pulse)

Timing Considerations

• Fasted state enhances GH release
• Wait 20-30 minutes before eating
• Can eat to manage appetite effect
• Avoid high-fat meals close to injection

The Saturation Dose

• ~100 mcg represents saturation per dose
• Higher doses don't proportionally increase GH
• But may increase appetite and side effects
• 100 mcg 2-3x daily often optimal

Reconstitution

• Use bacteriostatic water
• Standard: 5mg vial + 2.5ml water = 2mg/ml
• Refrigerate after reconstitution
• Stable for 4-6 weeks
• Protect from light

Synergy & Stacking

The GHRH + GHRP Synergy

Multiplicative Effect

Combining GHRH analog with GHRP-2 creates synergy:

• GHRP-2 suppresses somatostatin ("releases brake")
• GHRH presses the "accelerator"
• Combined effect is multiplicative, not additive
• 3-10x greater GH release than either alone

Common Combinations

GHRP-2 + CJC-1295 (No DAC)

Most popular stack:

• 100-200 mcg GHRP-2
• 100-200 mcg CJC-1295 (Mod GRF 1-29)
• 2-3x daily (same injection)
• Maximizes GH pulse amplitude

GHRP-2 + Sermorelin

Traditional combination:

• 100 mcg GHRP-2
• 100-200 mcg Sermorelin
• Can be combined in same syringe
• Well-established protocol

GHRP-2 + CJC-1295 with DAC

For sustained elevation:

• CJC-1295 with DAC: 1-2x per week
• GHRP-2: 2-3x daily
• Provides both baseline elevation and pulses
• Higher cost approach

When to Choose GHRP-2

Choose GHRP-2 over alternatives when:

• Want potent GH release
• Some appetite stimulation acceptable/desired
• Looking for balance between GHRP-6 and Ipamorelin
• Budget allows for mid-tier option

Comparison: GHRP-2 vs Alternatives

Safety

Known Side Effects

Common

• Moderate appetite increase
• Water retention (dose-dependent)
• Fatigue/drowsiness (especially bedtime dose)
• Tingling/numbness (high doses)
• Headache (usually temporary)

Less Common

• Flushing
• Joint aches
• Mild cortisol elevation
• Mild prolactin elevation

Compared to GHRP-6

• Less intense hunger
• Similar water retention potential
• Similar cortisol/prolactin effects
• Slightly better tolerability overall

Contraindications

Avoid or use with caution if:

• Active cancer or cancer history
• Diabetic (glucose effects possible)
• History of prolactinoma
• Pregnancy or breastfeeding
• Under 18 (without medical supervision)

Drug Interactions

• May affect glucose metabolism
• Potential interaction with diabetes medications
• Caution with corticosteroids
• Generally compatible with most medications

Monitoring

Baseline Assessments

• IGF-1 level
• Fasting glucose/HbA1c
• Prolactin (optional)
• Body composition

During Use

• IGF-1 (every 3-6 months)
• Weight and composition tracking
• Appetite and side effect logging
• Glucose if diabetic

Signs to Monitor

• Excessive water retention
• Carpal tunnel symptoms
• Persistent fatigue
• Glucose changes

Regulatory

Current Status

Legal Considerations

• Available as research chemical in most countries
• Not approved for therapeutic use (except Japan diagnostics)
• Athletes: Strictly banned in competition
• Quality varies by supplier

Clinical Status

GHRP-2 (Pralmorelin) is:

• The only GHRP approved for any medical use
• Used diagnostically in Japan since 2004
• Provides validation of efficacy and safety
• May pave way for future therapeutic approvals

References